Canada's Spartan Bioscience Launches POC DNA Testing System for PGx Applications

The first available test on the system, for the CYP2C19*2 mutation that guides how patients metabolize the anti-coagulant Plavix, is currently in a clinical trial in Canada. The company expects that data from the study will help support regulatory filings around the world for the platform.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.